Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?

Abstract

Atypical antipsychotics are nowadays the most widely used drugs to treat schizophrenia and other psychosis. Unfortunately, some of them can cause major metabolic adverse effects, such as weight gain, dyslipidemia and type 2 diabetes. The underlying lipogenic mechanisms of the antipsychotic drugs are not known, but several studies have focused on a central effect in the hypothalamic control of appetite regulation and energy expenditure. In a functional convergent genomic approach we recently used a cellular model and demonstrated that orexigenic antipsychotics that induce weight gain activate the expression of lipid biosynthesis genes controlled by the sterol regulatory element-binding protein (SREBP) transcription factors. We therefore hypothesized that the major genes involved in the SREBP activation of fatty acids and cholesterol production (SREBF1, SREBF2, SCAP, INSIG1 and INSIG2) would be strong candidate genes for interindividual variation in drug-induced weight gain. We genotyped a total of 44 HapMap-selected tagging single nucleotide polymorphisms in a sample of 160 German patients with schizophrenia that had been monitored with respect to changes in body mass index during antipsychotic drug treatment. We found a strong association (P=0.0003–0.00007) between three markers localized within or near the INSIG2 gene (rs17587100, rs10490624 and rs17047764) and antipsychotic-related weight gain. Our finding is supported by the recent involvement of the INSIG2 gene in obesity in the general population and implicates SREBP-controlled lipogenesis in drug-induced metabolic adverse effects.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–1696.

    CAS  PubMed  Google Scholar 

  2. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290–296.

    Article  PubMed  Google Scholar 

  3. Meyer JM, Koro CE . The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70: 1–17.

    Article  PubMed  Google Scholar 

  4. Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Järvelin MR, Laurén LH et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry 2005; 66: 559–563.

    Article  PubMed  Google Scholar 

  5. Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006; 163: 1273–1276.

    Article  PubMed  Google Scholar 

  6. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334–1349.

    Article  PubMed  Google Scholar 

  7. Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB . Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry 2007; 64: 242–249.

    Article  PubMed  Google Scholar 

  8. Arranz MJ, de Leon J . Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007; 12: 707–747.

    Article  CAS  PubMed  Google Scholar 

  9. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28: 519–526.

    Article  CAS  PubMed  Google Scholar 

  10. Matsui-Sakata A, Ohtani H, Sawada Y . Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005; 20: 368–378.

    Article  CAS  PubMed  Google Scholar 

  11. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH . Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci 2007; 104: 3456–3459.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL . Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001; 62: 45–66.

    CAS  PubMed  Google Scholar 

  13. Theisen FM, Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Wehmeier PM, Krieg JC et al. Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs. Psychiatry Genet 2005; 15: 285–289.

    Article  Google Scholar 

  14. Müller DJ, Kennedy JL . Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006; 7: 863–887.

    Article  PubMed  Google Scholar 

  15. Chagnon YC . Susceptibility genes for the side effect of antipsychotics on body weight and obesity. Curr Drug Targets 2006; 7: 1681–1695.

    Article  CAS  PubMed  Google Scholar 

  16. Reynolds GP, Zhang ZJ, Zhang XB . Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002; 359: 2086–2087.

    Article  CAS  PubMed  Google Scholar 

  17. Reynolds GP, Zhang Z, Zhang X . Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003; 160: 677–679.

    Article  PubMed  Google Scholar 

  18. Templeman LA, Reynolds GP, Arranz B, San L . Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet 2005; 15: 195–200.

    Article  CAS  Google Scholar 

  19. Lane HY, Lin CC, Huang CH, Chang YC, Hsu SK, Chang WH . Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders. Schizophr Res 2004; 67: 63–70.

    Article  PubMed  Google Scholar 

  20. Ryu S, Cho EY, Park T, Oh S, Jang WS, Kim SK et al. 759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 673–677.

    Article  CAS  PubMed  Google Scholar 

  21. Theisen FM, Hinney A, Bromel T, Heinzel-Gutenbrunner M, Martin M, Krieg JC et al. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatry Genet 2004; 14: 139–142.

    Article  Google Scholar 

  22. Ferno J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ et al. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics 2005; 5: 298–304.

    Article  CAS  Google Scholar 

  23. Raeder MB, Ferno J, Glambek M, Stansberg C, Steen VM . Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neuroscience Let 2006; 395: 185–190.

    Article  CAS  Google Scholar 

  24. Ferno J, Skrede S, Vik-Mo AO, Håvik B, Steen VM . Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci 2006; 7: p 69.

    Article  Google Scholar 

  25. Dietschy JM, Turley SD . Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 2004; 45: 1375–1397.

    Article  CAS  PubMed  Google Scholar 

  26. Edwards PA, Tabor D, Kast HR, Venkateswaran A . Regulation of gene expression by SREBP and SCAP. Biochim Biophys Acta 2000; 1529: 103–113.

    Article  CAS  PubMed  Google Scholar 

  27. Horton JD, Goldstein JL, Brown MS . SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125–1131.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Nakamura MT, Cheon Y, Li Y, Nara TY . Mechanisms of regulation of gene expression by fatty acids. Lipids 2004; 39: 1077–1083.

    Article  CAS  PubMed  Google Scholar 

  29. Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, Aebersold R et al. Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell 2002; 110: 489–500.

    Article  CAS  PubMed  Google Scholar 

  30. Rawson RB . Control of lipid metabolism by regulated intramembrane proteolysis of sterol regulatory element binding proteins (SREBPs). Biochem Soc Symp 2003; 70: 221.

    Article  CAS  Google Scholar 

  31. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL . Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 1997; 99: 846–854.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Horton JD, Shimomura I, Brown MS, Hammer RE, Goldstein JL, Shimano H . Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J Clin Invest 1998; 101: 2331–2339.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL . Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest 1996; 98: 1575–1584.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Eberlé D, Clément K, Meyre D, Sahbatou M, Vaxillaire M, Le Gall A et al. SREBF-1 gene polymorphisms are associated with obesity and type 2 diabetes in French obese and diabetic cohorts. Diabtes 2004; 53: 2153–2157.

    Article  Google Scholar 

  35. Herbert A, Gerry NP, McQueen MB, Heid IM, Pfeufer A, Illig T et al. A common genetic variant is associated with adult and childhood obesity. Science 2006; 312: 279–283.

    Article  CAS  PubMed  Google Scholar 

  36. Lyon HN, Emilsson V, Hinney A, Heid IM, Lasky-Su J, Zhu X et al. The association of a SNP upstream of INSIG2 with body mass index is reproduced in several but not all cohorts. PLoS Genet 2007; 3: e61.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Bromel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998; 3: 76–80.

    Article  CAS  PubMed  Google Scholar 

  38. Theisen FM, Linden A, Geller F, Schafer H, Martin M, Remschmidt H et al. Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication. J Psychiatr Res 2001; 35: 339–345.

    Article  CAS  PubMed  Google Scholar 

  39. Gordon D . Viewing and Editing Assembled Sequences Using Consed. Current Protocols in Bioinformatics, In: Baxevanis AD, Davison DB (eds). Current Protocols in Bioinformatics. John Wiley: New York, 2004, pp 11.12.11–11.12.43.

    Google Scholar 

  40. Nyholt DR . A simple correction for multiple testing for SNPs in linkage disequilibrium with each other. Am J Hum Genet 2004; 74: 765–769.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Dina C, Meyre D, Samson C, Tichet J, Marre M, Jouret B et al. Comment on ‘A common genetic variant is associated with adult and childhood obesity’. Science 2007; 315: 187.

    Article  CAS  PubMed  Google Scholar 

  42. Loos RJ, Barroso I, O'rahilly S, Wareham NJ . Comment on ‘A common genetic variant is associated with adult and childhood obesity’. Science 2007; 315: 187.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Rosskopf D, Bornhorst A, Rimmbach C, Schwahn C, Kayser A, Kruger A et al. Comment on ‘A common genetic variant is associated with adult and childhood obesity’. Science 2007; 315: 187.

    Article  CAS  PubMed  Google Scholar 

  44. Hall DH, Rahman T, Avery PJ, Keavney B . INSIG-2 promoter polymorphism and obesity related phenotypes: association study in 1428 members of 248 families. BMC Med Genet 2007; 30: 83.

    Google Scholar 

  45. Kumar J, Sunkishala RR, Karthikeyan G, Sengupta S . The common genetic variant upstream of INSIG2 gene is not associated with obesity in Indian population. Clin Genet 2007; 71: 415–418.

    Article  CAS  PubMed  Google Scholar 

  46. Smith AJ, Cooper JA, Li LK, Humphries SE . INSIG2 gene polymorphism is not associated with obesity in Caucasian, Afro-Caribbean and Indian subjects. Int J Obes 2007; 31: 1753–1755.

    Article  CAS  Google Scholar 

  47. Feng Y, Dong H, Xiang Q, Hong X, Wilker E, Zhang Y et al. Lack of association between rs7566605 and obesity in a Chinese population. Hum Genet 2007; 120: 743–745.

    Article  PubMed  Google Scholar 

  48. Skelly T, Pinheiro AP, Lange LA, Sullivan PF . Is rs7566605, a SNP near INSIG2, associated with body mass in a randomized clinical trial of antipsychotics in schizophrenia? Mol Psychiatry 2007; 12: 321–322.

    Article  CAS  PubMed  Google Scholar 

  49. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–1223.

    Article  CAS  PubMed  Google Scholar 

  50. Cervino AC, Li G, Edwards S, Zhu J, Laurie C, Tokiwa G et al. Integrating QTL and high-density SNP analyses in mice to identify Insig2 as a susceptibility gene for plasma cholesterol levels. Genomics 2005; 86: 505–517.

    Article  CAS  PubMed  Google Scholar 

  51. Yabe D, Komuro R, Liang G, Goldstein JL, Brown MS . Liver-specific mRNA for Insig-2 down-regulated by insulin: implications for fatty acid synthesis. Proc Natl Acad Sci 2003; 100: 3155–3160.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Bai YM, Lin CC, Chen JY, Lin CY, Su TP, Chou P . Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry 2006; 163: 1276–1279.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The present study is grounded on an initial microarray-based gene expression analysis on antipsychotic drug action, using the infrastructure provided by the Norwegian Microarray Consortium FUGE technology platform (www.microarray.no), funded by the FUGE programme of the Research Council of Norway. The study has been supported by grants from the Research Council of Norway (including FUGE grant no. 151904, ‘Senter for grunnleggende sykdomsmekanismer’, Mental Health program and PSYKISKHELSE grant no. 175345), Helse Vest RHF and Dr Einar Martens Fund. MMN received support for this work from the Alfried Krupp von Bohlen und Halbach-Stiftung. JH and AH receive funding via the German National Genome Net. We are indebted to the patients for their participation in this study. We also thank CIGENE, the FUGE/Research Council of Norway-funded national SNP platform, for genotyping our samples.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S Le Hellard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Le Hellard, S., Theisen, F., Haberhausen, M. et al. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?. Mol Psychiatry 14, 308–317 (2009). https://doi.org/10.1038/sj.mp.4002133

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.mp.4002133

Keywords

This article is cited by

Search

Quick links